News from ophthalix inc

Jun 09, 2014, 07:00 ET

OphthaliX Provides an Update on its Clinical Developments and Strategic Plans

 OphthaliX Inc. (OTCQB: OPLI), announced today an update on its clinical developments and strategic plans: - Glaucoma - The Company is...

Dec 31, 2013, 07:00 ET

OphthaliX to Conduct a Retrospective Analysis of the Phase III Dry Eye Syndrome Study Data Based on the A3 Adenosine Receptor Biomarker

 OphthaliX Inc. (OTCQB: OPLI), announced today that it will conduct a retrospective analysis of the Phase III Dry Eye Syndrome study data to...

Dec 30, 2013, 01:30 ET

OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome

 OphthaliX Inc. (OTCQB: OPLI), announced today results from a 24 week, placebo-controlled phase III study involving 237 patients with...

Oct 02, 2013, 13:11 ET

OphthaliX to Present at the Ophthalmology Futures European Forum

OphthaliX Inc. (OTC BB: OPLI), announced today that Dr. Sari Fishman, Director of Clinical Affairs, will deliver a company presentation at the...

Sep 03, 2013, 16:30 ET

European Patent Office Grants a Patent for the Treatment of Sjogren's Syndrome

 OphthaliX Inc. (OTC BB: OPLID), announced today that the European Patent Office issued a Certificate of Grant of Patent for European Patent...

Jul 16, 2013, 17:44 ET

OphthaliX to Initiate a Phase II study of CF101 for the Treatment of Uveitis

 OphthaliX Inc. (OTC BB: OPLI), announced today the submission of a Phase II study protocol of its drug candidate, CF101, for the treatment of...

May 10, 2013, 16:36 ET

Third Party Presented New Data at the ARVO 2013 Annual Meeting in Seattle, WA, Validating the use of A3 Adenosine Receptor Agonists for Lowering Intra Ocular Pressure and for the Treatment of Glaucoma

 OphthaliX, Inc. (OTC BB: OPLI), announced today that it has come to its knowledge that Professor M. Francesca Cordeiro, a Professor of...

Mar 15, 2013, 17:08 ET

OphthaliX Inc. Announces the Completion of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study

 OphthaliX Inc. (OTCBB: OPLI) announced today that it has completed patient enrollment for a Phase 3 clinical study of CF101 for the treatment...

Dec 12, 2012, 17:42 ET

Dr. Gil Ben-Menachem appointed Chief Executive Officer of OphthaliX Inc.

 OphthaliX Inc. (OTCBB: OPLI) today announced that it has appointed Dr. Gil Ben-Menachem as Chief Executive Officer effective January 1, 2013....

May 15, 2012, 18:04 ET

OphthaliX Reports First Quarter 2012 Financial Results

 OphthaliX (OTCBB: OPLI) today reported its financial and operating results for the quarter ended March 31, 2012. OphthaliX is an advanced...

Apr 09, 2012, 13:22 ET

OphthaliX Successfully Completed Preclinical Studies Showing the Efficacy of CF101 for the Treatment of Anterior Uveitis

OphthaliX (OTCBB: OPLI) announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating...

Feb 21, 2012, 17:24 ET

OphthaliX Announces Issuance of Chinese Patent for the Treatment of Dry Eye Disorders

OphthaliX (OTCBB: OPLI) announced that the Chinese State Intellectual Property Office (SIPO) issued a Certificate of Patent Invention for Chinese...

Feb 06, 2012, 17:21 ET

OphthaliX Announces the Appointment of Prof. Roger Kornberg as a Director

 OphthaliX Inc. (OTCBB: OPLI) is pleased to announce the appointment of Professor Roger D. Kornberg to the Company's Board of Directors....

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets